Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a ProblemThe Motley Fool • 08/07/26
Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label ExpansionSeeking Alpha • 08/07/26
3 Medical Stocks Standing Out After Crushing Q2 Earnings ExpectationsZacks Investment Research • 08/06/26
Eli Lilly's Weight-Loss Drug Demand Is Nearly Limitless. Here's What Comes Next for the $1 Trillion Drugmaker24/7 Wall Street • 08/05/26
LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance RaisedZacks Investment Research • 08/05/26
Stock Market Midday, Aug. 5: Eli Lilly Pops and AMD Drops in Mixed Morning MarketsThe Motley Fool • 08/05/26
Eli Lilly Q2 Earnings Review: Breath-Taking Results Mean Higher Ceiling On Stock Price TargetSeeking Alpha • 08/05/26
Lilly (LLY) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/05/26